Zevra Revenue Jumps 486 Percent in Q2
Zevra Therapeutics (NASDAQ:ZVRA), a biopharmaceutical company focused on rare diseases, announced its Q2 2025 financial results on August 12, 2025.
The most notable headline was a sharp year-over-year revenue increase and a swing to GAAP profitability, primarily driven by the completion of a major priority review voucher (PRV) sale.
GAAP revenue of $25.9 million outpaced the consensus estimate of $22.56 million, while diluted earnings per share (GAAP) of $1.21 fell short of the expected $2.26, but were clouded by sizeable non-cash charges related to OLPRUVA and the one-time nature of the PRV sale. Overall, the period demonstrated commercial momentum in key assets, but exposed the operational risks present in rare disease drug launches.
Source Fool.com
